B. ARV Activity of Stampidine in Chronically FIV-Infected Cats++ |
Stampidine Dose Level (mg/kg xbid) |
Log10 FIV-load in PBMC |
Log Reduction of FIV-load |
Average Log Reduction Mean±SE (P-value) |
| Pre |
Post |
| 50 (#1) |
1 |
0 |
1 |
1.33±0.33 (P=0.008) |
| 50 (#2) |
2 |
0 |
1 |
| 50 (#3) |
1 |
0 |
1 |
| 100 (#1) |
2 |
1 |
1 |
1.25±0.25 (P=0.002) |
| 100 (#2) |
3 |
2 |
2 |
| 100 (#3) |
2 |
0 |
1 |
| 100 (#4) |
2 |
1 |
1 |
| Placebo (#1) |
1 |
2 |
-1 |
-2.0±0.6 |
| Placebo (#2) |
2 |
5 |
-2 |
| Placebo (#3) |
2 |
4 |
-3 |
+The anti-HIV activity of Stampidine against BR/92/019, a genotypically and phenotypically NRTI-resistant HIV-1 isolate was evaluated in Hu-PBL-SCID mice. Stampidine
was administered via gavage or by addition to the food starting on the day of virus inoculation. Throughout the experimental period, mice were monitored daily for morbidity
and mortality. Two weeks after virus inoculation, Hu-PBL-SCID mice were electively killed, and their peritoneal lavage cells as well as spleen cells were examined for
evidence of HIV-1 infection by NASBA. At the time of necropsy, 18 selected tissues were submitted for standard hispathological examinations.
* Log10 HIV-load (Mean±SE): 4.4±1.0
++The anti-retroviral activity of Stampidine was examined in chronically FIV-infected shorthair domestic cats, as described in Materials and Methods. The FIV load of
PBMCs from Stampidine- treated vs. placebo-treated cats was determined in standard PBMC co-culture experiments, as previously reported (30). |